🌍September 16, 2026·1d agodiscovery

CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’

Publisher

Fierce Biotech

Global

This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.

Read original

At a glance

Publisher: Fierce Biotech
Region: Global
Scope: discovery
Published: September 16, 2026
Language: EN

Publisher context, original article off-platform

This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.

Source route

Continue on news.google.com

Leave the platform to read the original full article on the publisher site.

Source: Fierce Biotech

Scope: discovery

Open original article

Related coverage

More related coverage

Yahoo Finance/23h ago

Cyllene Therapeutics Appoints Seasoned Biotech Executive Dr Marc Grasso as Chief Financial Officer

TAPinto/23h ago

Hovione Pharmaceutical Company Opens 31K Sq. Ft. Facility in East Windsor, Adding Area Jobs

Fierce Biotech/23h ago

Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech

STAT/1d ago

CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’

More related coverage

Cyllene Therapeutics Appoints Seasoned Biotech Executive Dr Marc Grasso as Chief Financial Officer

Hovione Pharmaceutical Company Opens 31K Sq. Ft. Facility in East Windsor, Adding Area Jobs

Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech

A Sellas immunotherapy study, long delayed, will end in failure